181 search results for: Pathophysiology
IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.
IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Presentation highlights from the ADVENT symposium on smell loss and nasal congestion in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Engage with experts Klaus Rabe, Stephanie Christenson, and Paola Rogliani in an educational symposium to explore the inflammatory pathways and phenotypes of COPD, investigate the genetic associations of IL-33 and COPD, examine early preclinical findings, and review ongoing research on the role of IL-33 in COPD.
CRSwNP Interactive Patient Case Tool
Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.
COPD and Asthma: What's the Difference and Is There a Link?
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
